These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 2862087

  • 21. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC, Schneider J.
    Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
    [Abstract] [Full Text] [Related]

  • 22. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 23. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach, Koledova E, Metcalfe S, Hultman C, Milicevic Z, Romania/Russia Mix25 Study Group.
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [Abstract] [Full Text] [Related]

  • 24. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 25. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
    Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G.
    Diabete Metab; 1994 Oct 18; 20(1):15-9. PubMed ID: 8056129
    [Abstract] [Full Text] [Related]

  • 26. Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction.
    Ascić-Buturović B, Kacila M.
    Bosn J Basic Med Sci; 2008 Nov 18; 8(4):309-12. PubMed ID: 19125700
    [Abstract] [Full Text] [Related]

  • 27. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.
    Diabetes Care; 1998 May 18; 21(5):701-5. PubMed ID: 9589227
    [Abstract] [Full Text] [Related]

  • 28. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ, Scism-Bacon JL, Zagar AJ.
    Diabetes Obes Metab; 2006 Jul 18; 8(4):448-55. PubMed ID: 16776752
    [Abstract] [Full Text] [Related]

  • 29. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ, Pans M, Rubin CJ.
    Clin Ther; 2003 Mar 18; 25(3):890-903. PubMed ID: 12852706
    [Abstract] [Full Text] [Related]

  • 30. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
    Osei K, Falko JM.
    Am J Med Sci; 1985 Apr 18; 289(4):148-53. PubMed ID: 3920907
    [Abstract] [Full Text] [Related]

  • 31. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec 18; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 32. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.
    Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E.
    Diabet Med; 2006 Jul 18; 23(7):736-42. PubMed ID: 16842477
    [Abstract] [Full Text] [Related]

  • 33. Insulin therapy in type II diabetes.
    Holman RR, Turner RC.
    Diabetes Res Clin Pract; 1995 Aug 18; 28 Suppl():S179-84. PubMed ID: 8529512
    [Abstract] [Full Text] [Related]

  • 34. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM.
    Metabolism; 2004 Feb 18; 53(2):159-64. PubMed ID: 14767866
    [Abstract] [Full Text] [Related]

  • 35. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS.
    JAMA; 1998 Jan 14; 279(2):137-43. PubMed ID: 9440664
    [Abstract] [Full Text] [Related]

  • 36. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 37. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
    Karl D, Zhou R, Vlajnic A, Riddle M.
    Diabet Med; 2012 Jul 01; 29(7):933-6. PubMed ID: 22413808
    [Abstract] [Full Text] [Related]

  • 38. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, Hattersley AT, Patel KA, UNITED study.
    Diabetologia; 2018 Dec 01; 61(12):2520-2527. PubMed ID: 30229274
    [Abstract] [Full Text] [Related]

  • 39. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 Dec 01; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 40. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D, Diamant M.
    Diabetes Obes Metab; 2015 Feb 01; 17(2):145-51. PubMed ID: 25323312
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.